eszopiclone and levocetirizine

A "chiral switch" occurs in the pharmaceutical market when a drug made up of 2 enantiomer forms is replaced with a purified single-enantiomer version, often in the context of a patent expiration. We studied the prevalence of chiral switching in the United States over the past decade, including trends in use of, and expenditures on, these products in Medicaid.. Retrospective analysis.. We used US Adopted Names prefixes (lev/levo/ar/es/dex/dextro) to identify all single-enantiomer drugs approved from 2001 to 2011. From publicly available US Food and Drug Administration (FDA) approval documents, we extracted the characteristics of the pivotal premarket trials for the single enantiomers. Specifically, we evaluated whether the single enantiomer was directly compared with the precursor racemic drug and whether there was evidence of superior efficacy. We used quarterly drug expenditure data from each state Medicaid program to chart trends in use of, and spending on, the single-enantiomer products and their racemic precursors during the study period.. From 2001 to 2011, the FDA approved 9 single-enantiomer products: dexlansoprazole, levoleucovorin, levocetirizine, armodafinil, arformoterol, eszopiclone, escitalopram, dexmethylphenidate, and esomeprazole. Of those 9 drugs, 3 had at least 1 pre-approval randomized trial that included the racemic precursor as a direct comparator, but there was no evidence of superiority of the single enantiomer over the racemic at comparable doses. Between 2001 and 2011, US Medicaid programs spent approximately $6.3 billion on these 9 single-enantiomer drugs.. Recently approved single-enantiomer drugs showed no evidence of superior efficacy over the older racemic precursors in the pivotal trials leading to their approval, and in a majority of cases, they were not directly compared.

Topics: Antidotes; Azabicyclo Compounds; Benzhydryl Compounds; Bronchodilator Agents; Central Nervous System Stimulants; Cetirizine; Dexlansoprazole; Dexmethylphenidate Hydrochloride; Drug Approval; Drug Prescriptions; Drugs, Generic; Esomeprazole; Eszopiclone; Ethanolamines; Formoterol Fumarate; Histamine H1 Antagonists, Non-Sedating; Humans; Hypnotics and Sedatives; Levoleucovorin; Medicaid; Modafinil; Patents as Topic; Piperazines; Proton Pump Inhibitors; Retrospective Studies; Stereoisomerism; United States; United States Food and Drug Administration; Wakefulness-Promoting Agents